Nkarta, Inc.
General ticker "NKTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $151.1M (TTM average)
Nkarta, Inc. follows the US Stock Market performance with the rate: 38.2%.
Estimated limits based on current volatility of 8.5%: low 2.51$, high 2.97$
Factors to consider:
- Total employees count: 150 (-8.0%) as of 2023
- Top business risk factors: Pandemic risks, Manufacturing risks, Supply chain disruptions, Cybersecurity threats, Limited operating history
- Current price 10.3% above estimated high
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.97$, 3.15$]
- 2026-12-31 to 2027-12-31 estimated range: [1.12$, 3.42$]
Financial Metrics affecting the NKTX estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -66.23 <= 0.07
- Positive: Shareholder equity ratio, % of 77.27 > 64.25
- Positive: Investing cash flow per share per price, % of 74.91 > -0.65
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term NKTX quotes
Long-term NKTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $131.65MM | $128.19MM | $121.21MM |
| Operating Income | $-131.65MM | $-128.19MM | $-121.21MM |
| Non-Operating Income | $14.84MM | $19.40MM | $17.12MM |
| R&D Expense | $96.77MM | $96.74MM | $90.43MM |
| Income(Loss) | $-116.81MM | $-108.79MM | $-104.08MM |
| Profit(Loss)* | $-117.50MM | $-108.79MM | $-104.08MM |
| Stockholders Equity | $273.29MM | $407.98MM | $312.32MM |
| Assets | $378.88MM | $501.20MM | $404.21MM |
| Operating Cash Flow | $-86.16MM | $-99.70MM | $-88.70MM |
| Capital expenditure | $28.15MM | $4.41MM | $1.21MM |
| Investing Cash Flow | $79.02MM | $-129.56MM | $100.32MM |
| Financing Cash Flow | $0.69MM | $226.08MM | $0.14MM |
| Earnings Per Share** | $-2.40 | $-1.60 | $-1.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.